Inflammatory Disease patents
This page is updated frequently with new Inflammatory Disease-related patent applications.
|Biomarkers and methods for measuring and monitoring inflammatory disease activity|
Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.
Oklahoma Medical Research Foundation
|Il-17a/f heterologous polypeptides and therapeutic uses thereof|
The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17f designated herein as interleukin 17a/f (il-17a/f). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
|Suprametallogels and uses thereof|
The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y.
Massachusetts Institute Of Technology
|Method and system for targeting the microbiome to promote health and treat inflammatory diseases|
A method and system of reducing the likelihood of an inflammatory disease developing by providing a mucosal adhesive strip to a subject, with the strip provided with at least one of a plurality of agents effective to hinder the growth of spirochetes bacteria in a subject's oral cavity. In certain embodiments, an effective amount of prevotella intermedia is provided to decrease the incidence of periodontitis and to reduce the progression of alzheimer's disease.
|Withaferin a analogs and uses thereof|
The present invention provides a novel class of withanolides that have been isolated from w. Somnifera under aeroponic conditions or produced semi-synthetically from withanolide natural products.
Arizona Board Of Regents On Behalf Of The University Of Arizona
|Substituted amino triazoles useful as human chitinase inhibitors|
Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase.
Oncoarendi Therapeutics Sp. Z O.o.
|Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 h)-quinolone|
Said aryl, heteroaryl, cycloalkyl and heterocyclyl groups being unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, c1-c4 alkyl, c1-c4 hydroxyalkyl, c1-c4 alkoxy, c1-c4 haloalkyl, c1-c4 haloalkoxy, —sor, —so2r, —nr′r″, —nr′(c═o)r″, —coor, nitro and cyano substituents, wherein r, r′ and r″ are the same or different and each represents a hydrogen atom or c1-c4 alkyl group.. .
|Composition for use in treating and/or preventing human condition, disorder or diseases|
Composition comprising a metal and/or a semimetal, a sodium salt, a tranquilizer, a halogen, a carotenoid, grain, and a neutral gel for example for use in treating and/or preventing a condition, disorder or disease such as pain, metabolic diseases, fatigue, absence of appetite, cramps, immune diseases, inflammatory disease, cancer, neurological and/or psychiatric diseases.. .
|Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors|
Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are bruton's tyrosine kinase (btk) inhibitors.
Zhejiang Dtrm Biopharma Co. Ltd.
|Salts and solid form of a btk inhibitor|
Disclosed herein are processes for preparing 2-[(3r)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (i)), salts of compound (i) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (i) or a pharmaceutically acceptable salt thereof..
Principia Biopharma Inc.
Fumarate analogs and uses thereof
Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes..
Rigel Pharmaceuticals, Inc.
Tricyclic inhibitors of poly(adp-ribose)polymerase
The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2h)-one derivatives. The compounds are potent inhibitors of the enzyme poly(adp-ribose)polymerase (parp), particularly parp-1 and potentially parp-2.
Newgen Therapeutics, Inc.
There are provided compounds of formula (i) as defined in the specification which are p38 map kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.. .
Topivert Pharma Limited
Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons.. .
Method of providing monoclonal auto-antibodies with desired specificity
Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human auto-immunosome and corresponding monoclonal antibody reservoir are provided.
[means for solution] the present inventors have studied on a pam activity on an α7 nach receptor, and they have found that a tetrahydrooxepinopyridine compound has a pam activity on an α7 nach receptor, thereby completing the present invention. The tetrahydrooxepinopyridine compound of the present invention has a pam activity on an α7 nach receptor and can be expected as an agent for preventing or treating dementia, cognitive impairment, schizophrenia, alzheimer's disease, cias, negative symptoms of schizophrenia, inflammatory diseases, or pain..
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Inhibiting the transient receptor potential a1 ion channel
The present invention relates to compounds of the formula (i), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the transient receptor potential a1 ion channel (trpa1).. .
Hydra Biosciences, Inc.
New compounds i
And their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or n-oxides, which are inhibitors of ssao activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of ssao activity is beneficial, such as inflammatory diseases and immune disorders..
Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaecutical use
The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (ndga) compounds and butane bridge modified tetra-o-substituted ndga compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as hiv infection, hpv infection, or hsv infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.. .
Erimos Pharmaceuticals Llc
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
The disclosure relates to prostaglandin receptor ep2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which ep2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof..
Anti-human il-21 antibodies
Monoclonal antibodies are identified that bind the il-21 protein. These antibodies are used to identify regions of the il-21 protein to where binding neutralizes il-21 activity.
Reversible pegylation of nanocarriers
The present invention relates to the preparation and use of reversibly pegylated nanocarriers. The reversibly peggylated nanocarrier system comprises an inner core comprising or consisting of a nanoparticle and/or at least one pharmaceutical compound; optionally at least one lipid bilayer on the surface of the inner core; a first ligand bound to the surface of said inner core, or if present, to the surface of the at least one lipid bilayer; a second ligand bound to the first ligand, the second ligand being covalently bound to poly(ethylene glycol) or a derivative thereof.
Drug delivery conjugates for treating resistant cancer and for use in combination therapy
Described herein are drug delivery conjugates for targeted therapy. In particular, described herein are drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids that are useful for treating cancers and inflammatory diseases.
Novel compounds useful for the treatment of degenerative and inflammatory diseases
The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. Asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g.
Compositions and methods for delivery of kinase inhibiting peptides
The invention relates to compositions and methods for the treatment of inflammatory disease states. In particular, the invention relates to the use of a nanoparticle incorporated kinase inhibiting peptide to treat inflammatory disease states..
Purdue Research Foundation
Saa-domain-specific antibodies and peptide antagonists and use thereof to treat inflammatory diseases
Isolated saa peptides, fusion proteins and compositions comprising such are provided as are domain-specific saa antibodies. Methods of treating sepsis and endotoxemia are also provided..
The Feinstein Institue For Medical Research
Heterocyclic compounds and uses thereof
The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, egfr (including her), alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, btk, or jak, and the respective pathways.. .
Acea Biosciences Inc.
Compositions and methods for treating neoplasia, inflammatory disease and other disorders
The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a bet family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone n-terminal tail)..
Dana-farber Cancer Institute, Inc.
Wherein qx represents —c(o)o—c1-4 alkyl, or a salt or protected derivative thereof, and other compounds that are useful in the preparation of compounds that have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; syk kinase; and members of the src family of tyrosine kinases) and has use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.. .
Novel sulphur containing lipids for use as food supplement or as medicament
The present disclosure relates to lipid compounds of the general formula (i): (i) wherein r1 is selected from a c10-c22 alkyl, a c10-c22 alkenyl having 1-6 double bonds, and a c10-c22 alkynyl having 1-6 triple bonds; r2 and r3 are the same or different substituents; y is selected from sulphur, sulfoxide, and sulfone; and x represents a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, complex or solvate thereof. The disclosure also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area..
Pronova Biopharma Norge As
Mmf-derivatives of ethyleneglycols
The present invention relates to novel compounds, e.g. For use as a medicament.
Compositions and methods for treating severe pain
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.. .
Infirst Healthcare Limited
Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease..
UniversitÉ Paris Descartes
Autoimmunity and multiple sclerosis treatment
A method for alleviating a symptom of multiple sclerosis or other autoimmune or inflammatory disease includes a step of identifying a subject having multiple sclerosis or other autoimmune diseases. A fasting mimicking diet is administered to the subject for a first predetermined time period, the fasting mimicking diet providing less than 50% of the subject's normal caloric intake.
University Of Southern California
Natural and synthetic compounds for treating cancer and other diseases
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, cns, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins.
Pacific Arrow Limited
Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
A method and system for targeting the microbiome to promote health involves exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies and autoimmune diseases. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..
Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
Biomarkers useful for assessing inflammatory disease or flare activity, in particular in juvenile idiopathic arthritis, are provided, along with kits for measuring expression of the biomarkers. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples..
Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
The present invention relates to compositions and methods for preparing splice variants of tnfalpha receptor (tnfr) in vivo or in vitro, and the resulting tnfr protein variants. Such variants may be prepared by controlling the splicing of pre-mrna molecules and regulating protein expression with splice switching oligonucleotides or splice switching oligomers (ssos).
Roche Innovation Center Copenhagen A/s
The present invention provides for compounds of formula (i) wherein rx, x, y, y1, l1, a1, a2, a3, a4, a5, a6, a7, and a8, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and aids. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (i)..
Inhibitors of bruton's tyrosine kinase
Disclosed herein are amido compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Inhibition of hypoxia-inducible factor activity with carica papaya extracts
An extract of carica papaya leaves obtained from a plant of age six months and younger from the date of germination of the seed is used as an inhibitor of hif to effectively block hypoxia-inducible factor (hif) function and methods of use thereof. More specifically it relates to the use of the carica papaya plant extract to eliminate unwanted cells by inhibiting hif in the prevention and treatment of hypoxia-related conditions and diseases such as inflammatory diseases, vascular diseases, cancer and infectious diseases.
Universiti Putra Malaysia
Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
Such compositions can also further comprise various components such as lipids (for example fatty acids, esters thereof or derivatives thereof). Such compositions can be used for example in methods for treating an inflammatory diseases chosen from inflammatory bowel diseases, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, acute lung injury, bronchopulmonary dysplasia, cystic fibrosis, bronchitis, bronchiolitis, arthritis, osteoarthritis, ankylosing spondylitis and rheumatism..
Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
The present invention provides a heterocyclic compound having a tlr7, tlr9, tlr7/8, tlr7/9 or tlr7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof..
Takeda Pharmaceutical Company Limited
Pharmaceutical composition comprising stem cells treated with nod2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases
The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expressing nucleotide-binding oligomerization domain protein 2 (nod2) or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a graft comprising stem cells expressing nod2, a method for preparing the graft, a composite comprising stem cells expressing nod2, and a culture generated by culturing the nod2-expressing stem cells..
Kang Stem Biotech Co., Ltd
Treatment of inflammatory diseases using placental stem cells
Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (alibert-bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.. .
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4 -yl) oxy) napththalen-1 - yl) ureas as p38 map knase inhibitors
There are provided compounds of formula (i) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and copd.. .
Anti-mcam antibodies and associated methods of use
The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain. The invention also provides pharmaceutical compositions, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer..
Prothena Biosciences Limited
Targeting agent antibody conjugates and uses thereof
Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells.
The Scripps Research Institute
Anti-c5a binding moieties with high blocking activity
The present invention relates to binding moieties that specifically bind to a conformational epitope of c5a, in particular human c5a. Preferred binding moieties are anti-c5a antibodies that bind to this conformational epitope.
Inflammatory Disease topics:
Pharmaceutically Acceptable Salt
Follow us on Twitter
This listing is a sample listing of patent applications related to Inflammatory Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Inflammatory Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.